Wire · opportunities
Eli Lilly to offer early access to next-gen obesity drug to some patients
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 31 August 2026 · Fusion42 review
Eli Lilly is offering early access to retatrutide, an experimental obesity drug targeting GLP-1, GIP, and glucagon, for a limited group of patients with refractory obesity and serious complications before FDA approval, with a formal FDA filing expected in early 2027.
This Wire brief sits within Fusion42's coverage of Health, and 3 sources have reported it between 23 Jul 2026 and 4 Aug 2026.
◆ ◆ The Wire takeaway
You can now reach patients excluded from trials by offering early access to new obesity drug retatrutide before FDA approval; this opens a market for innovative treatments ahead of formal regulation.
◆ Coverage
3 sources · first reported 23 Jul 2026 · latest 4 Aug 2026
◆ Related on Wire
◆ Topics